AT
BMRN icon

American Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

American Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,318
Closed -$201K – 297
2023
Q2 		$201K Sell
2,318
-306
-12% -$28.8K 0.01% 401
2023
Q1 		$255K Sell
2,624
-83
-3% -$8.61K 0.02% 349
2022
Q4 		$280K Sell
2,707
-51
-2% -$4.79K 0.03% 321
2022
Q3 		$229K Sell
2,758
-60
-2% -$5.34K 0.02% 351
2022
Q2 		$234K Buy
2,818
+70
+3% +$5.57K 0.02% 376
2022
Q1 		$212K Sell
2,748
-152
-5% -$12.7K 0.01% 460
2021
Q4 		$256K Buy
+2,900
New +$239K 0.02% 274

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

American Trust's BMRN Position: Q3 2023 in Review

American Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 2,318 shares — an estimated $201K sold.

American Trust first reported a position in BMRN in Q4 2021 and held it in 7 quarters. The position peaked at $280K in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • American Trust reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • American Trust sold 2,318 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $201K.
  • American Trust first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • American Trust's BioMarin Pharmaceuticals position peaked at $280K in Q4 2022.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on American Trust's 13F filing for Q3 2023, filed 15 Nov 2023.